Long term follow up in type A insulin resistant syndrome treated by insulin-like growth factor I

Hiromi Ishihama, Yoshimi Suzuki, Kanji Muramatsu, Miseho Nagai, Minoru Kokubo, Hisayuki Shiraya, Akira Kawakita, Yutaka Nishimura, Takeshi Imamura, Masashi Kobayashi

Abstract
Insulin-like growth factor I (IGF-I) is a useful therapeutic agent in insulin resistant diabetes mellitus due to insulin receptor disease because of its hypoglycaemic effects through the IGF-I receptor. A girl with typical type A insulin resistant syndrome was treated with IGF-I for two years and the treatment was effective in ameliorating hyperglycaemia. Overproduction of testosterone in polycystic ovaries was aggravated with this treatment, however. Therefore, IGF-I treatment may be used for glycaemic control but with caution because of its possible side effect of aggravating hyperandrogenism in these patients. (Arch Dis Child 1994; 71: 144–146)

The characteristic features of type A insulin resistant syndrome are extreme insulin resistance, acanthosis nigricans, and ovarian hyperandrogenism. The mechanism of the insulin resistance is either a defect in insulin receptor itself or postreceptor abnormality. Recently, several investigators have reported various mutations or deletions of insulin receptor gene in this disorder,1–3 which cause decreased receptor number, decreased binding affinity, or abnormality in signal transduction due to a kinase defect. On the other hand, although it has been speculated that acanthosis nigricans and ovarian hyperandrogenism originate from secondary hyperinsulinaemia, the precise mechanism is still unclear.4

Insulin-like growth factor I (IGF-I) has growth promoting activity and also metabolic effects through the IGF-I receptor. Therefore, IGF-I may be an appropriate therapeutic agent for type A insulin resistant syndrome. We treated a girl with typical type A insulin resistant syndrome with IGF-I for two years to observe whether these clinical features may be affected by the treatment.

Case report
The patient was a girl, aged 11 years, who was found to have glucosuria on a routine urine screening test. There was neither a history of parental consanguinity nor a family history of diabetes mellitus. She was 144 cm in height (–0.72 SD) and her body weight was 40.5 kg (–0.07 SD). She had amenorrhoea, acanthosis nigricans in her axilla, and marked hirsutism on the face and extremities. An oral glucose tolerance test revealed a diabetic pattern and hyperinsulinaemia. At 120 minutes, plasma glucose concentration was 19.0 mmol/l and plasma insulin was above 1920 pmol/l. Insulin tolerance tests (0.1 U/kg and 0.3 U/kg) showed no significant effect on the plasma glucose concentration. Exogenous insulin (0.3 U/kg) lowered the plasma glucose only to 60% of the previous value. Glycated haemoglobin (HbA1c) was raised (7.0%, normal range 3.5–5.5%). Ultrasonographic examination demonstrated polycystic ovaries. Neither anti-insulin nor anti-insulin receptor antibody were detectable in her serum. These findings showed that she had type A insulin resistant syndrome. She was observed without regular insulin treatment.

Methods
The method for the 125I-insulin binding to erythrocytes, transformed lymphocytes, and cultured fibroblasts has been described by Sasaoka et al.5,6 Surface labelling of Epstein-Barr virus transformed lymphocytes was determined by the method described previously.7 We performed subsequent DNA analysis of insulin receptor gene by a modification of the method described by Kusukawa et al.8 and examined transfection of insulin receptor cDNA to COS7 cells according to the method of Kobayashi et al.9

Recombinant human IGF-I was provided by the Fujisawa pharmaceutical industry (Osaka, Japan). Treatment was started at the age of 13 years after informed consent was obtained from the patient and her parents. Lyophilised IGF-I freshly dissolved in normal saline was injected subcutaneously before breakfast and supper every day. The initial dose, which was determined by the dose trial study, was 0.25 mg/kg/dose. She did not receive any other medication. Blood sampling was done on admission and thereafter every three months to evaluate her plasma glucose profile, HbA1c, fructosamine, plasma insulin, and total IGF-I. Routine haematological and biochemical examinations were also performed at the same time. Serum testosterone concentration was serially examined every four months after treatment. Height and weight were measured on each admission. A luteinising hormone releasing hormone (LH–RH) stimulation test was carried out at pretreatment and 19 months after the treatment.

Results
Insulin binding to erythrocytes, transformed lymphocytes, and cultured fibroblasts was
Long term follow up in type A insulin resistant syndrome treated by insulin-like growth factor I

Discussion

Type A insulin resistant syndrome has been proved to be due to abnormalities of insulin receptor molecule by recent gene technology. Some patients with this disease may require massive doses of exogenous insulin for diabetic control, but most do not adequately respond to insulin treatment. From this viewpoint, we treated such a patient with IGF-I and found that the long term IGF-I administration was very effective for glycaemic control in type A insulin resistant syndrome.

There was another reason for selecting IGF-I as the choice for treatment of extreme insulin resistant syndrome with mild diabetes mellitus such as in our case. Namely, we expected IGF-I might improve acanthosis nigricans and ovarian hyperandrogenism by decreasing plasma insulin concentrations as it has been suggested that these features are due to hyperinsulinaemia. However, serum testosterone was increased by the treatment. Furthermore, it decreased in proportion to the reduced dose of IGF-I and again increased moderately as hyperinsulinaemia returned with the interruption of IGF-I treatment. These findings not only suggested that IGF-I administration could aggravate overproduction of testosterone in type A insulin receptor disease, but also supported animal experimental data that showed that IGF-I as well as insulin was capable of augmenting androgen synthesis in ovarian theca interstitial cells. In our patient, IGF-I treatment seemed to cause a different therapeutic effect on acanthosis nigricans and hyperandroge

We are grateful to Dr Fumihiro Mizutani and Dr Haruyo Inagaki (Nagoya City University, Aichi, Japan) for their clinical support.

Clinical course showing concentrations of fasting plasma glucose and insulin, HbA1c, and fructosamine. (Dates are shown year/month.)

decreased to 14–35% of normal. A surface labelling study in transformed lymphocytes demonstrated a decreased number in insulin receptors. Subsequent DNA analysis of insulin receptor gene revealed a heterozygous point mutation substituting codon TGG for TTG in exon 20 which changed Trp193 of insulin receptor to Leu. Furthermore, insulin binding to the COS7 cell transfected with the mutant c-DNA was decreased to 28% of normal.

After the administration of IGF-I, plasma glucose, plasma insulin, HbA1c, and fructosamine concentrations became normalised as shown in the figure. Serum concentrations of IGF-I were raised from 15–33 nmol/l to 60–116 nmol/l. During the treatment, the patient did not have any hypoglycaemic attacks or abnormal routine laboratory data. Acanthosis nigricans also seemed to improve gradually. On the contrary, hirsutism, particularly her moustache and beard hair, became worse and her serum testosterone concentration slowly increased, although there was no significant change in the LH–RH stimulation test at pretreatment and 19 months after the treatment. Polycystic ovaries were unchanged on ultrasonographic approach throughout the clinical course. Interestingly, the testosterone concentration decreased in parallel with reducing the dose of IGF-I to avoid the possible influence of IGF-I on testosterone production and hirsutism. IGF-I treatment was finally stopped at the patient’s and parents’ request. Consequently, her plasma glucose, plasma insulin, HbA1c, and fructosamine concentrations increased and serum testosterone also returned to raised values. Height gain was not achieved by the treatment probably due to her advanced bone age which was already 14-8 years old at the time of the start of the treatment.

We are grateful to Dr Fumihiro Mizutani and Dr Haruyo Inagaki (Nagoya City University, Aichi, Japan) for their clinical support.
Ishihama, Suzuki, Muramatsu, Nagai, Kokubo, Shiraya, Kawakita, Nishimura, Imamura, Kobayashi


Long-term follow up in type A insulin resistant syndrome treated by insulin-like growth factor I.

H Ishihama, Y Suzuki, K Muramatsu, M Nagai, M Kokubo, H Shiraya, A Kawakita, Y Nishimura, T Imamura and M Kobayashi

Arch Dis Child 1994 71: 144-146
doi: 10.1136/adc.71.2.144

Updated information and services can be found at:
http://adc.bmj.com/content/71/2/144

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/